HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $13 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $13 price target.
Read original at benzingaStocks · News reference
Evolus Announces Expanded Symatese Agreement For Exclusive Estyme HA Gel Rights In Canada, Australia, New Zealand; Terms Not Disclosed
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 4, 2026, 12:35 PM
- Checked
- Aug 4, 2026, 12:35 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Evolus Q2 EPS $(0.12), Sales $84.084M Beat $81.603M Estimate
Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 0 percent. This is a 47.83 percent increase over losses of $(0.23) per share from the same
Read original at benzingaEvolus Raises FY2026 Sales Guidance from $327.000M-$337.000M to $330.000M-$337.000M vs $330.445M Est
Evolus (NASDAQ:EOLS) raises FY2026 sales outlook from $327.000 million-$337.000 million to $330.000 million-$337.000 million vs $330.445 million estimate.
Read original at benzinga8-K filing — Evolus, Inc. (EOLS)
Filed: 2026-08-04 AccNo: 0001570562-26-000083 Size: 203 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgar